Search Result

Results for "

transplantation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (4) Bacterial (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) CD28 (1) CD3 (1) CFTR (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (3) Drug Metabolite (3) Endogenous Metabolite (2) Glucosidase (1) Glutaminase (1) Histone Demethylase (1) Integrin (2) Interleukin Related (1) Liposome (6) LPL Receptor (1) Nucleoside Antimetabolite/Analog (2) PKC (2) PROTACs (1) SARS-CoV (1) TAM Receptor (4) TGF-beta/Smad (1) Topoisomerase (1) VEGFR (1) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (22) Cardiovascular Disease (6) Infection (3) Inflammation/Immunology (27) Metabolic Disease (3) Neurological Disease (2)

By Targets:

Antibiotic (1)

Apoptosis (4)

Bacterial (1)

Biochemical Assay Reagents (1)

c-Met/HGFR (1)

CD28 (1)

CD3 (1)

CFTR (1)

DNA Alkylator/Crosslinker (2)

DNA/RNA Synthesis (3)

Drug Metabolite (3)

Endogenous Metabolite (2)

Glucosidase (1)

Glutaminase (1)

Histone Demethylase (1)

Integrin (2)

Interleukin Related (1)

Liposome (6)

LPL Receptor (1)

Nucleoside Antimetabolite/Analog (2)

PKC (2)

PROTACs (1)

SARS-CoV (1)

TAM Receptor (4)

TGF-beta/Smad (1)

Topoisomerase (1)

VEGFR (1)

Wnt (2)

β-catenin (2)

By Research Areas:

Cancer (22)

Cardiovascular Disease (6)

Infection (3)

Inflammation/Immunology (27)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160214

Perforin-IN-2	Others	Inflammation/Immunology
Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marrow/stem cell transplantation. Perforin-IN-2 binds to plasma proteins with a binding rate of 99.8%. Perforin-IN-2 requires a higher concentration (> 900 μM) to achieve optimal perforin inhibition in vivo. Perforin-in-2 can effectively inhibit the lytic activity of recombinant perforin on Jurkat T (IC₅₀=6.65 μM) leukemia cells, and also inhibit the death of K562 leukemia target cells .

HY-108852

Basiliximab CHI 621	Interleukin Related	Inflammation/Immunology
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .

HY-108813

Belatacept BMS 224818; LEA 29Y	Others	Inflammation/Immunology
Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants .

HY-110217

BMS-566419	Others	Others
BMS-566419 is an acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase (IMPDH). Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in the de novo synthesis of guanosine nucleotides. BMS-566419 has clinical utility for the research of transplant rejection .

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease .

HY-134259

MEISi-2	Others	Cancer
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .

HY-146497

Topoisomerase I inhibitor 7	Topoisomerase	Cancer
Topoisomerase I inhibitor 7 (Compound 8) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 7 significantly inhibits tumor growth (up to 79%) and increases the lifespan (153%) of mice bearing P388 lymphoma transplants. Topoisomerase I inhibitor 7 indicates prospects for further search of new antitumor agent candidates among the heteroarene-fused anthraquinones .

HY-P99152

Muromonab	CD3	Inflammation/Immunology Cancer
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .

HY-P99376

Narsoplimab OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)	SARS-CoV	Infection
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .

HY-147579

Axl-IN-12	TAM Receptor	Infection Inflammation/Immunology Cancer
Axl-IN-12 (Example 2) is a potent AXL inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .

HY-147578

Axl-IN-11	TAM Receptor	Infection Inflammation/Immunology Cancer
Axl-IN-11 (Example 1) is a potent AXL inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .

HY-12319A

Cardiogenol C hydrochloride	β-catenin Wnt	Cardiovascular Disease
Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC₅₀=100 nM) . Cardiogenol C hydrochloride also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C hydrochloride is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models .

HY-12319

Cardiogenol C	β-catenin Wnt	Cancer
Cardiogenol C is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC₅₀=100 nM) . Cardiogenol C also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models .

HY-147577

Axl-IN-10	TAM Receptor	Inflammation/Immunology Cancer
Axl-IN-10 (Example 1) is a potent AXL inhibitor, with an IC₅₀ of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .

HY-147576

Axl-IN-9	TAM Receptor	Inflammation/Immunology Cancer
Axl-IN-9 (Example 10) is a potent AXL inhibitor, with an IC₅₀ of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .

HY-15448

Tezacaftor Maximum Cited Publications 8 Publications Verification VX-661	CFTR	Cancer
Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-157746

CTPS1-IN-1	DNA/RNA Synthesis	Inflammation/Immunology Cancer
CTPS1-IN-1 (compound R80) is a CTPS1 inhibitor. CTPS1-IN-1 has the potential to research cancer (such as promoting vascular injury or surgical recovery) and immune system diseases (such as rejection of transplanted cells and tissues, transplant-related diseases or disorders, allergies, and autoimmune diseases) .

HY-119320

Ethimidine

Aethimidinum
Others Cancer

Ethimidine (Aethimidinum) can reduce the blood serum free SH (sulfhydryl) in in rats previously transplanted with sarcoma or carcinoma cells .
HY-N12396

Cyclosporin U

Others Inflammation/Immunology

Cyclosporin U (SMP0V32C6L) is an cytostatic agent that plays an important role in preventing rejection of transplanted organs .

Ethimidine Aethimidinum	Others	Cancer
Ethimidine (Aethimidinum) can reduce the blood serum free SH (sulfhydryl) in in rats previously transplanted with sarcoma or carcinoma cells .

Cyclosporin U	Others	Inflammation/Immunology
Cyclosporin U (SMP0V32C6L) is an cytostatic agent that plays an important role in preventing rejection of transplanted organs .

HY-P99512

Zampilimab UCB-7858	Glutaminase	Inflammation/Immunology
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant .

HY-149428

AD4 1 Publications Verification	PROTACs	Cancer
AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC₅₀: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .

HY-157374

Beef Heart Infusion	Biochemical Assay Reagents	Others
Beef Heart Infusion is a non-selective microbial culture medium formulation. Beef Heart Infusion provides nutrients for microbial growth. Beef Heart Infusion can be used for the culture, transplantation and rejuvenation of microorganisms.

HY-111320

Chrysomycin B	Bacterial Antibiotic	Cancer
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. Chrysomycin B causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B suppresses the growth of transplantable tumors in mice.

HY-A0126A

Epoprostenol sodium Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Endogenous Metabolite	Cardiovascular Disease
Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-13641

Mitobronitol Myelobromol; DBM	DNA Alkylator/Crosslinker	Cancer
Mitobronitol (Myelobromol; DBM) is a brominated analog of mannitol, also known as an anticancer agent that is classified as an alkylating agent. Mitobronitol has potential for myelosuppression associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia .

HY-P99765

Odulimomab anti-LFA1	Integrin	Inflammation/Immunology
Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease .

HY-W099331

Monoethylglycinexylidide hydrochloride MEGX hydrochloride; Norlidocaine hydrochloride	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Monoethylglycinexylidide (MEGX) hydrochloride is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver. Monoethylglycinexylidide has proven to be a highly sensitive indicator of hepatic dysfunction, especially in the field of liver transplantation .

HY-112531

Poly(2-hydroxyethyl methacrylate) (MW 20000)	Others	Others
Poly(2-hydroxyethyl methacrylate) (MW 20000) is one of the most important hydrogels in the biomaterials world. Poly(2-hydroxyethyl methacrylate) is the basic component of contact lenses, and is also used in implantation of soft tissues, synthetic transplant for gristle and bone, regeneration of neurotic tissue, transmission of agent and etc .

HY-112531A

Poly(2-hydroxyethyl methacrylate) (MW 1000000)	Others	Others
Poly(2-hydroxyethyl methacrylate) (MW 1000000) is one of the most important hydrogels in the biomaterials world. Poly(2-hydroxyethyl methacrylate) is the basic component of contact lenses, and is also used in implantation of soft tissues, synthetic transplant for gristle and bone, regeneration of neurotic tissue, transmission of agent and etc .

HY-A0126AR

Epoprostenol sodium (Standard) Prostaglandin I2 sodium salt (Standard); Prostacyclin sodium salt (Standard); Flolan (Standard)	Endogenous Metabolite	Cardiovascular Disease
Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-122788

N-Oleoyl serinol Oleoyl serinol	Apoptosis	Cancer
N-Oleoyl serinol is a ceramide analog that can be used in stem cell therapy to prevent stem cells from developing into teratomas. N-Oleoyl serinol induces apoptosis in residual pluripotent embryoid body-derived cells (EBCs), prevents teratoma formation, and enriches EBC cells that undergo neural differentiation after transplantation .

HY-N2022

Castanospermine 2 Publications Verification	Glucosidase	Inflammation/Immunology Cancer
Castanospermine is a natural alkaloid that can be extracted from black beans or the Moreton Bay chestnut tree (Castanospermum australae). Castanospermine is an α/ β-glucosidase inhibitor. Castanospermine has anti-inflammatory, antiviral replication and anti-metastatic effects on prostate cancer. Castanospermine can be used as an immunosuppressant to prevent transplant rejection .

HY-147207

Phospholipid-PEG-Biotin (MW 1000)	Liposome	Others
Phospholipid-PEG-Biotin (MW 1000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207C

Phospholipid-PEG-Biotin (MW 5000)	Liposome	Others
Phospholipid-PEG-Biotin (MW 5000) is a phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .

HY-147207B

Phospholipid-PEG-Biotin (MW 3400)	Liposome	Others
Phospholipid-PEG-Biotin (MW 3400) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207D

Phospholipid-PEG-Biotin (MW 10000)	Liposome	Others
Phospholipid-PEG-Biotin (MW 10000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207E

Phospholipid-PEG-Biotin (MW 20000)	Liposome	Others
Phospholipid-PEG-Biotin (MW 20000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-118530

Bucillamine SA96; Thiobutarit	VEGFR	Cardiovascular Disease Inflammation/Immunology
Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .

HY-147207A

Phospholipid-PEG-Biotin (MW 2000)	Liposome	Others
Phospholipid-PEG-Biotin (MW 2000) is a Biotin labeled phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .

HY-137455

Terevalefim

ANG-3777
c-Met/HGFR Inflammation/Immunology

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .

Terevalefim ANG-3777	c-Met/HGFR	Inflammation/Immunology
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .

HY-125881

ASP1126	LPL Receptor	Inflammation/Immunology
ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC₅₀ values of 7.12 nM, 517 nM for hS1P₁ and hS1P₃, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile .

HY-155193

XY-52	Others	Inflammation/Immunology
XY-52 (Compound 32) is a Stimulation-2 (ST2) inhibitor, with an IC₅₀ value of 5.68 μM in AlphaLISA assay, and 4.59 μM in HEK-Blue assay. XY-52 increases proinflammatory T-cell proliferation. XY-52 reduces the plasma sST2 and IFNγ biomarkers in the graft versus host disease (GVHD) mice model .

HY-110086

RWJ 50271	Integrin	Inflammation/Immunology
RWJ 50271 is an selective and orally active inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC₅₀ of 5.0 μM (HL60 cells). RWJ 50271 inhibits LFA-1/ICAM-1-mediated cell adhesion .

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells .

HY-P99708

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935) .

HY-P5888

PKCε inhibitor peptide,myristoylated Myr‐PKCɛ-	PKC	Inflammation/Immunology
PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated PKC? peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-P5877

ɛPKC(85–92),Myristoylated	PKC	Inflammation/Immunology
?PKC(85–92),Myristoylated is a cell permeable myristic acid conjugated PKC? peptide activator that enhances NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-136650

Fludarabine triphosphate F-ara-ATP	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP), the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis .

HY-136650A

Fludarabine triphosphate trisodium F-ara-ATP trisodium	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis .

HY-13739

Ranimustine MCNU	DNA Alkylator/Crosslinker	Cancer
Ranimustine (MCNU) is a nitrosourea alkylating agent, can be used for research of chronic myelogenous leukemia and polycythemia vera .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library

2706 Compounds compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2706 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L079

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-157374

Beef Heart Infusion	Microbial Culture
Beef Heart Infusion is a non-selective microbial culture medium formulation. Beef Heart Infusion provides nutrients for microbial growth. Beef Heart Infusion can be used for the culture, transplantation and rejuvenation of microorganisms.

HY-147207

Phospholipid-PEG-Biotin (MW 1000)	Drug Delivery
Phospholipid-PEG-Biotin (MW 1000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207C

Phospholipid-PEG-Biotin (MW 5000)

Drug Delivery

Phospholipid-PEG-Biotin (MW 5000) is a phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .

HY-147207B

Phospholipid-PEG-Biotin (MW 3400)	Drug Delivery
Phospholipid-PEG-Biotin (MW 3400) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207D

Phospholipid-PEG-Biotin (MW 10000)	Drug Delivery
Phospholipid-PEG-Biotin (MW 10000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207E

Phospholipid-PEG-Biotin (MW 20000)	Drug Delivery
Phospholipid-PEG-Biotin (MW 20000) is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG-Biotin (MW 3400) can interact with avidinylated antibodies. Phospholipid-PEG-Biotin (MW 3400) can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .

HY-147207A

Phospholipid-PEG-Biotin (MW 2000)

Drug Delivery

Phospholipid-PEG-Biotin (MW 2000) is a Biotin labeled phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .

Cat. No.	Product Name	Target	Research Area

HY-P1973

Cyclosporin B	Peptides	Inflammation/Immunology
Cyclosporin B is a group of nonpolar cyclic oligopeptides with immunosuppressive activity. Cyclosporin B is used for the prevention of graft rejection in organ transplantation .

HY-P1917A

Uty HY Peptide (246-254) (TFA)	Peptides	Inflammation/Immunology
Uty HY Peptide (246-254) TFA, derived from the ubiquitously transcribed tetratricopeptide repeat gene on the Y chromosome (UTY) protein as an H-Y epitope, H-YD ^b, is a male-specific transplantation antigen H-Y .

HY-P1237

C-Type Natriuretic Peptide (CNP) (1-22), human 1 Publications Verification	Peptides	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-P1917

Uty HY Peptide (246-254)	Peptides	Inflammation/Immunology
Uty HY Peptide (246-254), derived from the ubiquitously transcribed tetratricopeptide repeat gene on the Y chromosome (UTY) protein as an H-Y epitope, H-YD ^b, is a male-specific transplantation antigen H-Y .

HY-P5888

PKCε inhibitor peptide,myristoylated Myr‐PKCɛ-	PKC	Inflammation/Immunology
PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated PKC? peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-P1237A

C-Type Natriuretic Peptide (CNP) (1-22), human TFA 1 Publications Verification	Peptides	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .